Quarterly report pursuant to Section 13 or 15(d)

Licensing, Collaborative and Other Arrangements (Details)

v2.4.0.6
Licensing, Collaborative and Other Arrangements (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended
Sep. 30, 2010
Sep. 30, 2012
Development Milestone [Member]
   
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Amount due upon achievement of milestone   8.5
Sales Milestone [Member]
   
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Amount due upon achievement of milestone   15.1
Collaborative Arrangement [Member]
   
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier   3
License fees paid $ 1.5